Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.20 USD
Change Today -0.05 / -0.31%
Volume 1.2M
DYAX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

dyax corp (DYAX) Snapshot

Open
$16.16
Previous Close
$16.25
Day High
$16.62
Day Low
$15.84
52 Week High
03/16/15 - $18.07
52 Week Low
05/1/14 - $6.05
Market Cap
2.2B
Average Volume 10 Days
1.3M
EPS TTM
$-0.10
Shares Outstanding
136.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DYAX CORP (DYAX)

dyax corp (DYAX) Related Bloomberg News

View More Bloomberg News

dyax corp (DYAX) Related Businessweek News

No Related Businessweek News Found

dyax corp (DYAX) Details

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. The company distributes KALBITOR through a network of wholesale, hospital, and specialty pharmacy arrangements. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b clinical study to treat HAE prophylactically. The company has agreements with CVie Therapeutics to develop and commercialize KALBITOR for the treatment of HAE and other angioedema indications in China, Hong Kong, and Macau; and Novellus Biopharma AG to develop and commercialize KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. It also has agreement with CMIC Co., Ltd. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other angioedema indications in Japan; and collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in various territories worldwide. Dyax Corp. was founded in 1989 and is headquartered in Burlington, Massachusetts.

124 Employees
Last Reported Date: 02/27/15
Founded in 1989

dyax corp (DYAX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $615.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $409.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $444.0K
Executive Vice President and General Counsel
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2013.

dyax corp (DYAX) Key Developments

Dyax Corp. Provides Earnings Guidance for the Year 2015

Dyax Corp. provided sales guidance for the year 2015. For the year 2015, the company forecast KALBITOR net sales in the range of $60 million to $70 million. Operating costs and expenses (cost of product sales, research and development expenses, and selling, general and administrative costs) to be in the range of $105-110 million.

Dyax Corp. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Twelve Months Ended December 31, 2014

Dyax Corp. reported unaudited consolidated earnings results for the fourth quarter and twelve months ended December 31, 2014. Total revenues for the fourth quarter ended December 31, 2014 were $26.0 million, as compared to $16.9 million for the comparable quarter in 2013. The company reported a net loss of $2.3 million, or $0.02 per basic and diluted share, as compared to a net loss of $2.0 million, or $0.02 per basic and diluted share, for the comparable quarter in 2013. Income from operations was $344,000 against $755,000 a year ago. Total revenues for the twelve months ended December 31, 2014 were $81.7 million, including $68.3 million of KALBITOR net sales, as compared to $53.9 million for the comparable period in 2013, which included $40.5 million of KALBITOR net sales. The 2014 revenues also included royalties of approximately $3.8 million based on the initial sales of CYRAMZA. For the twelve months ended December 31, 2014, the company reported a net loss of $11.9 million, or $0.09 per share attributable to common stockholders, as compared to a net loss of $27.8 million, or $0.26 per share, for the comparable period in 2013. Loss from operations was $1,235,000 against $17,125,000 a year ago.

Dyax Corp. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 02:35 PM

Dyax Corp. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 02:35 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Gustav A. Christensen, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAX:US $16.20 USD -0.05

DYAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioCryst Pharmaceuticals Inc $8.11 USD +0.01
Regeneron Pharmaceuticals Inc $448.38 USD -5.61
Salix Pharmaceuticals Ltd $172.63 USD +0.08
Shire PLC 5,310 GBp -90.00
View Industry Companies
 

Industry Analysis

DYAX

Industry Average

Valuation DYAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.1x
Price/Book 21.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYAX CORP, please visit www.dyax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.